Polyarticular Course Juvenile Idiopathic Arthritis research hub

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

This study is looking at a new medicine called filgotinib for children and teenagers aged 8-18 who have a type of arthritis called polyarticular-course juvenile idiopathic arthritis (JIA). It aims to see if the medicine is safe, well-tolerated, and helps with their symptoms.